why choose us

First received: July 26, 2024

Clinical Trial: Evaluation of the Pharmacokinetics and Safety of Inaxaplin in Participants With Mild or Moderate Hepatic Impairment

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Focal Segmental Glomerulosclerosis (FSGS)

Study Type: INTERVENTIONAL


Official Title: A Phase 1, Open-label Study to Assess the Pharmacokinetics and Safety of a Single Dose of Inaxaplin in Subjects With Mild or Moderate Hepatic Impairment and in Matched Healthy Subjects

Brief Summary: The purpose of this study is to evaluate the pharmacokinetics, safety and tolerability of Inaxaplin (IXP) in participants with mild or moderate hepatic impairment and in matched healthy participants.

Read more